
New Treatment for Plaque Psoriasis Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Study Examines Mechanisms of Rare Paradoxical Response to ART in HIV
In rare cases, patients with HIV can experience a paradoxical response to antiretroviral therapy known as extreme immune decline.
4. FDA OKs Pembrolizumab Combo Therapy for Advanced Renal Cell Carcinoma
This is the first indication for pembrolizumab (Keytruda, Merck) in advanced renal cell carcinoma.
3. Immunotherapy Method Seeks to 'Kick and Kill' HIV
Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.
2. Study: Statins Prevent Cardiovascular Events for Rheumatoid Arthritis
Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.
1. FDA Approves New Treatment for Moderate-to-Severe Plaque Psoriasis
Risankizumab-rzaa (Skyrizi, AbbVie) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































